North America Dominated The Worldwide HIV Diagnostics Market In 2018 As Product Approvals Increased In The Area

 

HIV Diagnostics

HIV diagnostics is critical in HIV prevention, treatment, care, and other support services. HIV diagnosis includes testing services in health-care facilities, as well as a variety of community-based initiatives and HIV self-testing. The global HIV diagnostics market was worth $3,050.8 million in 2018 and is predicted to grow at a 9.2 percent CAGR during the forecast period (2019-2027). Because of increased government measures to limit HIV infection, the HIV diagnostics market is likely to rise significantly. For example, the Ministry of Health and Family Welfare of the Government of India released the 'Test and Treat Policy for HIV' policy in April 2017, which is projected to increase the longevity and quality of life of persons afflicted with HIV.

 

Home testing is becoming increasingly popular. HIV diagnosis is motivating key manufacturers to focus on creating portable, simple-to-use, and quick-diagnostic tests. As a result, market growth is likely to accelerate. For example, the Therapeutic Goods Administration approved Atomo Diagnostics' Atomo HIV Self-Test for sale in Australia in November 2018. (TGA). It is the first and only HIV diagnostic self-test approved by Australia's national regulator. The HIV diagnostics market is predicted to increase significantly as industry competitors implement more agreement and collaboration techniques. For example, in September 2019, Mylan N.V. and Atomo Diagnostics announced a collaboration.

 

North America dominated the worldwide HIV Diagnostics Market in 2018 as product approvals increased in the area. For example, Vela Diagnostics got de novo FDA approval in November 2019 for its Sentosa SQ HIV-1 Genotyping Assay, which was created to detect HIV-1 genomic treatment resistance mutations (DRMs). Furthermore, Abbott Laboratories received World Health Organization Prequalification approval (WHO PQ) in May 2019 for m-PIMA HIV-1/2 VL, the first point-of-care viral load diagnostic test. The portable molecular point-of-care test is intended for use in resource-constrained environments. The prequalification designation qualifies the goods for procurement by United Nations organisations.

Comments

Popular posts from this blog

With the use of High-Frequency alternating current, Radiofrequency Ablation Device convert Electromagnetic Energy into Heat Energy

The Isocyanates Market to Witness Robust Growth in North America and Asia Pacific

Air Purifier works as a Sanitizer in the air which helps in reducing pollutants, allergens, and toxins